Sudarshan Chemical Industries Ltd Q2 FY26 Earnings Analysis

Published 4 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹7.2K Cr

Price

1,068

Market Cap

₹7.2K Cr

P/E Ratio

1959.9

Earnings Summary

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

📊 Revenue & Sales Performance

No information is provided regarding the same in the latest conference call.

📈 Profitability & Margins

No information is provided regarding the same in the latest conference call.

🏗️ Capital Expenditure Plans

No information is provided regarding the same in the latest conference call.

💰 Fundraising & Capital Structure

No information is provided regarding the same in the latest conference call.

📋 Order Book & Pipeline

No information is provided regarding the same in the latest conference call.

Key Metrics

Frequently Asked Questions

What were Sudarshan Chemical Industries Ltd Q2 FY26 results?

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

What is Sudarshan Chemical Industries Ltd share price analysis?

Sudarshan Chemical Industries Ltd currently shows a neutral. The stock trades at a P/E of 1959.9 with a market cap of ₹7,189. Investors should review the full earnings analysis for detailed insights.

Is Sudarshan Chemical Industries Ltd planning capital expenditure?

No information is provided regarding the same in the latest conference call.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

What Sudarshan Chemical Industries Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Aether Industries Ltd (Q2 FY26)

    Aether Industri. Q2 FY26 quarterly results analysis. Future Growth Expectations of Aether Industries Limited: - Sales revenue grew 35% YoY in Q1 FY '26, indica

  • Epigral Ltd (Q2 FY26)

    Epigral Q2 FY26 quarterly results analysis. - Epigral aims for consistent growth driven by expansion and diversification into multiproducts serving various indu

  • Tatva Chintan Pharma Chem Ltd (Q2 FY26)

    Tatva Chintan Q2 FY26 quarterly results analysis. - Expecting 20% to 25% growth in revenue for FY 2026 compared to FY 2025. Market Cap ₹4,023, P/E 76.8. AI-powe

  • Anupam Rasayan India Ltd (Q2 FY26)

    Anupam Rasayan Q2 FY26 quarterly results analysis. - Strong revenue growth expected in FY '26 and beyond, with overall growth of over 30% anticipated. Market Ca